Nicolas Portelange

Nicolas Portelange

Auto-generated profile, based on publicly available information

Nicolas Portelange

KiOmed Pharma, Herstal, Belgium

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2024 in Rheumatology and Therapy
Verified
Journal Article
Open access
PDF file
NLNils A. Lynen
Nils A. Lynen
CEChristoph Eichhorn
Christoph Eichhorn
NPNicolas Portelange
Nicolas Portelange
MCMickaël Chausson
Mickaël Chausson
WWWim Weyenberg
Wim Weyenberg
Introduction Evaluate the real-world efficacy of a single intra-articular injection of carboxymethyl-chitosan (CM-chitosan), a new product class for knee osteoarthritis (OA). Methods This post-marketing study included adult patients with knee OA, who received a single injection of 60 mg CM-chitosan (currently marketed as KioMedinevsone) according to the instructions for use. Follow-up was performed at weeks 1, 12, 24, and 36. Efficacy was evaluated using a Visual Analog Scale (VAS) score for pain, the Knee injury and Osteoarthritis Outcome Score (KOOS), Patient’s Global Assessment (PGA), and overall patient satisfaction. Results Forty-nine patients were included in the study. VAS pain score significantly decreased from a median of 49.0 mm at baseline to 24.0 mm at week 1 and to 18 mm at week 36. Pain improvement was stable since at week 36; 91.8% of patients confirmed pain reduction. All KOOS subscales (symptoms, pain, activities of daily living, sports and recreational activities, quality of life) improved significantly compared to baseline at all time points. KOOS pain improved progressively from a median of 58.3% at baseline (mean 56.2 ± 18.8%) to 86.1% (mean 74.1 ± 24%) at week 36 compared to baseline. Overall, more than 70% of patients reported a condition gain (PGA), matching well with the more than 75% of patients being satisfied with the treatment. At 6 months, 72.7% of the patients could be classified as responder according to the OMERACT-OARSI proposed set of responder criteria. Conclusion CM-chitosan showed a rapid onset of pain relief after 1 week and with a duration of 9 months. In a real-world setting, treatment with CM-chitosan would appear to be a potentially effective option to reduce pain and improve physical function and global condition in patients with knee OA, opening new perspectives in patients who are considered as refractory to current symptomatic therapies and where the unmet need is high. Trial Registration Number NCT04757051 (ClinicalTrials.gov).

14 February 2023 in The Open Rheumatology Journal
Verified
Journal Article
Open access
PEP.J. Emans
P.J. Emans
GSG. Skaliczki
G. Skaliczki
DHD. Haverkamp
D. Haverkamp
JBJ. Bentin
J. Bentin
MCM. Chausson
M. Chausson
NPN. Portelange
N. Portelange
Background: Symptomatic knee osteoarthritis (OA) is typically treated with hyaluronan-based intra-articular injections. Advanced knee OA patients are often unresponsive to hyaluronan. KiOmedine® Carboxymethyl-Chitosan (CM-Chitosan), a novel fluid implant, was safe and effective for treating symptomatic knee OA. Objective: The objective of this study is to describe the efficacy of a single injection of KiOmedine® CM-Chitosan in advanced knee OA. Methods: Patients with advanced knee OA enrolled in the APROOVE trial and treated with KiOmedine® CM-Chitosan were identified: subgroup-1, BMI >30 kg/m2 and/or Kellgren Lawrence (KL) grade III (n=39), and subgroup-2, BMI >30 kg/m2 and KL-grade III (n=8). Within-group analyses were performed using the WOMAC scores and OMERACT-OARSI responder criteria at 3 and 6 months. Results: In both subgroups, significant improvements in all WOMAC scores were observed at 3 and 6 months (p<0.001 for all comparisons). A high responder rate was observed at 3 and 6 months in subgroup-1 (63.2% and 65.8%) and in subgroup-2 (57.1% and 62.5%). Conclusion: This post hoc analysis of the APROOVE trial showed that a single intra-articular injection with KiOmedine® CM-Chitosan could be an effective therapeutic option for patients with advanced knee OA. Clinical trial registration number: Clinicaltrial.gov identifier: Net30679208.

4 April 2025 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
POPhilippe Van Overschelde
Philippe Van Overschelde
PVPieter Vansintjan
Pieter Vansintjan
NPNicolas Portelange
Nicolas Portelange
MCMickael Chausson
Mickael Chausson
WWWim Weyenberg
Wim Weyenberg
The 12-month efficacy and safety of a novel bioresorbable fluid implant based on CM-chitosan for intra-articular injection was evaluated in knee osteoarthritis (OA) patients with predictive factors of failure to viscosupplementation. This pilot single-blind randomized controlled study was conducted in 104 patients with at least one of the following OA phenotypes: tricompartmental OA, patellofemoral involvement, K&L grade III or IV and/or body mass index >30 ​kg/m2. Non-inferiority and superiority of CM-chitosan (KioMedineVSone) in reducing pain were evaluated compared Hylan G-F 20 (Synvisc-One). Efficacy was evaluated using the WOMAC scores, OMERACT-OARSI responder rates, TKA eligibility and events, patient and physician satisfaction. At 6 months post-injection, mean WOMAC pain reduction vs. baseline was 69.4 ​± ​25.5 ​% for the CM-chitosan group and 66.3 ​± ​26.15 ​% for the Hylan G-F 20 group (non-inferiority p ​= ​0.096; 95 ​% CI -16.94 ​%, 7.02 ​%). At 12 months, significant symptomatic improvement in both groups, with clinically important differences in WOMAC pain reduction in favor of CM-chitosan, were observed, including in the subgroups of patients with patellofemoral OA (Δ 11.5 ​%), obese patients (Δ 21.7 ​%) and patients eligible for TKA at baseline (Δ 13.5 ​%). CM-chitosan showed a high response rate (93.8 ​%), as well as high patient (93.8 ​%) and investigator (90.6 ​%) satisfaction. No new safety signals were identified. In this difficult-to-treat population, CM-chitosan was non-inferior to Hylan G-F 20, but did show clinically important, though not statistically significant, differences in pain reduction at 12 months. CM-chitosan was effective in improving OA symptoms and physical function for 12 months.